Targeting Inflammation in Primary Cardiovascular Prevention

Author(s): Federico Carbone, Luca Liberale, Aldo Bonaventura, Michele Cea, Fabrizio Montecucco

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 37 , 2016

Become EABM
Become Reviewer


Background: In the last decade, the development of anti-inflammatory strategies emerged as new trend in cardiovascular (CV) pharmacotherapy. Anti-inflammatory properties have been previously identified in different classes of drugs used in primary CV prevention. However, the extent to which the modification of inflammatory profile contributes in determining CV outcome remains controversial.

Methods: Focusing on potential beneficial effects in primary prevention, this narrative review provides a comprehensive and critical analysis of randomized clinical trials testing anti-inflammatory treatments in CV disease.

Results: As upstream regulator of the hepatic production of C-reactive protein, tumor necrosis factor-α, interleukin (IL)-6 and IL-1 pathways early emerged as potential targets for CV prevention. More recently, additional strategies targeting lipoprotein-associated phospholipase A2, pro-protein convertase subtilisin/kexin type 9, and intracellular pathways (such as p38 MAPK and different isoforms of NADPH oxidase) have been tested.

Conclusion: Conflicting results emerged from clinical trials, emphasized the need to characterize the inflammatory profile of the patients, to minimize the heterogeneity of study populations and to clarify the true value of CRP as specific biomarker of atherosclerosis-related inflammation.

Keywords: Atherosclerosis, inflammation, tumor necrosis factor-α, interleukin-6, interleukin-1β, lipoprotein-associated phospholipase A2, pro-protein convertase subtilisin/kexin type 9, C-reactive protein.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [5662 - 5675]
Pages: 14
DOI: 10.2174/1381612822666160822124546
Price: $65

Article Metrics

PDF: 32
PRC: 1